Cyclosporine A as a Primary Treatment for Panniculitis-like T Cell Lymphoma: A Case with a Long-Term Remission.
- Author:
Won Sup LEE
1
;
Ji Hyen HWANG
;
Moon Jin KIM
;
Se Il GO
;
Anna LEE
;
Haa Na SONG
;
Min Jeong LEE
;
Myung Hee KANG
;
Hoon Gu KIM
;
Jeong Hee LEE
Author Information
1. Department of Internal Medicine, Institute of Health Sciences, Gyeongsang National University School of Medicine, Jinju, Korea. lwshmo@hanmail.net
- Publication Type:Case Report
- Keywords:
Subcutaneous panniculitis-like T cell lymphoma;
Cyclosporine A;
Remission
- MeSH:
Cyclosporine*;
Drug Therapy;
Fatal Outcome;
Humans;
Lymphoma;
Lymphoma, T-Cell*;
Panniculitis;
Subcutaneous Tissue;
T-Lymphocytes
- From:Cancer Research and Treatment
2014;46(3):312-316
- CountryRepublic of Korea
- Language:English
-
Abstract:
Subcutaneous panniculitis-like T cell lymphoma (SPTL) is a distinctive cutaneous lymphoma characterized by an infiltration of subcutaneous tissue by neoplastic T cells, similar to panniculitis. It is well-established that patients who are diagnosed with SPTL usually respond poorly to chemotherapy, showing fatal outcome. As a first line treatment for SPTL, anthracycline-based chemotherapy was most frequently used. For the treatment of SPTL, the efficacy of cyclosporine A has been recently reported in relapsed SPTL after anthracycline-based chemotherapy. However, it is still not clear whether cyclosporine A can be used as a first-line treatment against SPTL. Here, we report a case of SPTL, which achieved complete remission for nine years after first-line cyclosporine A therapy. This study suggests that cyclosporine A can induce a complete long-term remission as a first-line treatment.
